Peer-reviewed veterinary case report
Bovine hemoglobin treatment raises blood pressure in low-pressure cats
By Wehausen, Conni E et al.·Published in Journal of the American Veterinary Medical Association·2011·Animal Emergency Clinic, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of the effects of bovine hemoglobin glutamer-200 on systolic arterial blood pressure in hypotensive cats: 44 cases (1997-2008).
- Species:
- cat
Plain-English summary
A group of 44 cats with low blood pressure (systolic arterial blood pressure below 80 mm Hg) received a treatment called bovine hemoglobin glutamer-200 (Hb-200) to help raise their blood pressure. After treatment, 75% of the cats showed significant improvement, with their blood pressure rising above the critical level. Some cats experienced mild side effects like respiratory changes and vomiting, but overall, the treatment was effective. Unfortunately, only 39% of the cats survived to go home, while others either passed away or were euthanized due to their severe conditions.
People also search for: cat low blood pressure treatment · bovine hemoglobin for cats · hypotensive cat symptoms
Abstract
OBJECTIVE: To determine effects of bovine hemoglobin glutamer-200 (Hb-200) solution on systolic arterial blood pressure (SAP) in hypotensive cats and describe potential adverse effects associated with this treatment. DESIGN: Retrospective case series. ANIMALS: 44 cats. PROCEDURES: Medical records of hypotensive (Doppler SAP ≤ 80 mm Hg) cats that received Hb-200 treatment were reviewed. Volume and rate of Hb-200 administration, treatments for hypotension given prior to Hb-200 administration, changes in SAP, potential adverse effects, and short-term outcome were evaluated. RESULTS: 44 cats were included in the study. Mean ± SD SAP prior to Hb-200 administration was 52 ± 11 mm Hg, despite other treatments. Forty-three cats received Hb-200 via IV bolus administration (mean ± SD volume, 3.1 ± 2.2 mL/kg [1.41 ± 1.0 mL/lb] over 25.17 ± 17.51 minutes); 1 cat received a continuous rate infusion (CRI) only. The SAP increased to > 80 mm Hg in 33 of 44 (75%) cats. The SAP increased > 20 mm Hg above baseline value in 29 of these 33 cats and in 4 cats in which SAP did not exceed 80 mm Hg. A CRI (mean ± SD rate, 0.8 ± 0.5 mL/kg/h [0.36 ± 0.23 mL/lb/h]) of Hb-200 was administered to 37 cats (after bolus infusion in 36). Mean SAP during the CRI was 92 ± 18 mm Hg. Adverse effects included respiratory changes (n = 8 cats), vomiting (2), and pigmented serum (30). Seventeen (39%) cats survived to discharge from the hospital, 6 died, and 21 were euthanized. CONCLUSIONS AND CLINICAL RELEVANCE: Hb-200 effectively increased SAP in hypotensive cats with few adverse effects.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/21453180/